Institute of Human Virology H3Africa Biorepository (I-HAB) ADMIN SUPPLEMENT

项目摘要/摘要 尼日利亚人类病毒学研究所H3非洲生物库(I-HAB)，已成功 通过基于质量评估的迭代交互，将其实践升级为符合ISBER 利用Coriell成熟的模型进行能力建设，并毕业成为W/African H3非洲区域生物库，在新冠肺炎大流行期间，i-HAB失去了原计划的18个月 由于大流行导致服务中断而导致的活动。到目前为止，i-HAB只成功地 只从六个H3非洲研究项目中的一个项目中接收到所有DNA生物标本并进行了比对 支撑物。其中两个项目的保证金为67%和86%，而其余三个项目的保证金低于 50%提交；仅为0%、17%和29%。这份行政补充文件的目标是 (2022年7月1日至2023年6月30日)是为了确保所有剩余的生物质谱仪在 H3非洲调查员，均分，并在最后阶段使用，即分配均分 生物谱和数据提供给更广泛的科学界的研究人员，他们的应用已经 由数据和生物质学家咨询委员会(DBAC)批准进行高质量基因组学 和非洲的翻译研究，使用经过良好加工、保存和质量控制的 冗余保护的人体生物样本。为了实现这一目标，i-HAB建立在过去成功的基础上 解决四个具体目标。1)聘请PI完成沉积并创建主要等值线 符合GLP、ISBER指南和QC的人体生物样本和遗传物质 10%，符合H3非洲政策/指导方针。2)填充、查询和查询数据库 定期确保在线目录是最新的，并定期与其他两个区域联系 H3非洲生物资源库、H3Africa生物网络团队和相关利益相关者进行审查和集思广益 关于在预定会议期间填补差距的方法。3)有效分发高质量产品的试点程序 基于数据和生物样本，向更广泛的科学界提供高质量的生物样本 访问委员会的批准，并根据H3非洲的政策和指南。4)加强i-HAB 将商业模式作为长期可持续发展战略的一部分。与其他两个人协同工作 姊妹H3非洲生物库和H3非洲生物网，i-HAB继续倡导宿主 政府和社区的支持和试点进程，以使监管和道德进程 更轻松地共享样本和数据。通过扩大金融机构的规模获得强有力的制度支持 在IHVN的新设施中，生物仓库的规模超过了它的3倍，收购了一家液氮工厂， 其客户范围扩大到H3非洲以外的调查人员，标志着i- 哈布。

PROJECT SUMMARY/ABSTRACT The Institute of Human Virology Nigeria (IHVN) H3Africa biorepository (I-HAB), has successfully upgraded its practices to be ISBER compliant through an iterative quality assessment-based interaction involving capacity building drawing upon Coriell’s proven models and graduated to be the W/Africa H3Africa regional biorepository, During the COVID-19 pandemic, I-HAB lost 18 months of its planned activities due to the disruption of services by the pandemic. So far, I-HAB has only successfully received and aliquoted all DNA biospecimens from only one of the six H3Africa research projects that it supports. Two of the projects deposited 67% and 86% while the rest of the three projects are below 50% submission; at only 0%, 17%, and 29%. The goal of this administrative supplemental submission (1 JULY 2022 TO 30 JUNE 2023) is to ensure that all remaining biospecimens are deposited by H3Africa investigators, aliquoted, and used in the final phase which is to distribute aliquoted biospecimens and data to investigators from the wider scientific community whose application has been approved by the Data and Biospecimen Advisory Committee (DBAC) to conduct high-quality genomics and translational research in Africa using well processed, preserved and quality controlled and redundantly protected human biological samples. To achieve this, I-HAB builds on its past successes to address four specific aims. 1) Engage PIs to complete deposition and create sub-aliquots of primary human biologic samples and genetic materials in compliance with GLP, ISBER guidelines, and QC 10% in line with H3Africa policies/ guidelines. 2) Populate, interrogate, and query the database regularly to ensure that the online catalogue is up to date, interfacing regularly with other two regional H3Africa biorepositories, the H3AfricaBionet team, and relevant stakeholders to review and brainstorm on ways to address gaps during scheduled meetings. 3) Pilot processes for efficient distribution of high- quality biological samples to the wider scientific community, based on Data and Biological samples Access Committee approval and according to H3Africa policies and guidelines. 4) Strengthen I-HAB’s business model as part of a long-term sustainability strategy. Working collaboratively with the other two sister H3Africa biorepositories and the H3Africa Bionet, I-HAB continues to advocate for host government and community support and pilot processes to make the regulatory and ethical process of sharing samples and data easier. The strong institutional support through the expansion of the biorepository to over 3times its size at IHVN’s new facility, the acquirement of a liquid nitrogen plant, and the expansion of its clientele to investigators outside of H3Africa signals a sustainable future for I- HAB.